迪哲医药 Mediaroom - PR Newswire APAC

Dizal Showcases Robust Portfolio of Lung Cancer Studies at 2025 WCLC

SHANGHAI, Sept. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed t...

2025-09-09 18:00 1116

The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

* Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractor...

2025-08-06 19:02 1524

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

* ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins * Approva...

2025-07-03 08:08 2099

Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations

SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for it...

2025-06-19 18:08 2284

Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025

* Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in pe...

2025-06-12 18:13 1646

Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025

* DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic ...

2025-05-26 18:06 1995

Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences

* The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral T-cel...

2025-05-15 18:09 2280

Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025

* DZD8586 study results in B-cell non-Hodgkin lymphomas (B-NHLs) were selected for oral and poste...

2025-04-24 18:38 2224

Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting

SHANGHAI, April 1, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed t...

2025-04-01 18:18 2419

Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer

* Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTC...

2025-03-20 18:00 1769

U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application

* If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment op...

2025-01-07 18:00 1983

Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer

Sunvozertinib, as a single agent, demonstrated promising antitumor activity and favorable safety pr...

2024-12-11 18:05 2181

Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting

DZD8586 demonstrated encouraging anti-tumor activity with manageable safety and favorable pharmacok...

2024-12-09 18:00 1829

Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an or...

2024-11-08 18:01 1953

Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, O...

2024-10-13 16:04 2889

Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics

Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with ...

2024-09-17 15:47 2516

Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

* Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatme...

2024-06-19 19:30 2704

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

* Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20i...

2024-05-24 16:32 2373

Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting

Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be...

2024-04-24 22:10 2264

FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Dr...

2024-04-07 19:09 2926

Latest News